Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (111-120 of 218) with videos related to

Pageof 22
Sort By:
Scientific Reports|August 4, 2025
Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositisMagdalena Röckel, Luca Musella, Corinna Preusse, et al.
Journal of the National Cancer Institute|September 14, 2014
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaKlaus G Griewank, Rajmohan Murali, Joan Anton Puig-Butille, et al.
The Journal of Dermatology|April 11, 2020
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective studyTaisuke Matsuya, Yasuhiro Nakamura, Shigeto Matsushita, et al.
International Journal of Molecular Sciences|March 25, 2022
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint InhibitionLuca Hegedüs, Elisabeth Livingstone, Ágnes Bánkfalvi, et al.
Oncotarget|September 2, 2015
Analysis of SDHD promoter mutations in various types of melanomaSimone L Scholz, Susanne Horn, Rajmohan Murali, et al.
Cancers|May 14, 2022
Genetic and Clinical Characteristics of <i>ARID1A</i> Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalCarl Maximilian Thielmann, Johanna Matull, Sebastian Roth, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsAlvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyHelen Dearden, Lewis Au, Daniel Y Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Pediatric Blood & Cancer|November 5, 2025
Melanoma of the Choroid and Ciliary Body in Children: Remission of Metastatic Melanoma of the Choroid After Treatment With Chemotherapy and Immune Checkpoint InhibitionPia Tüller, Tobias Kiefer, Leyla Jabbarli, et al.
Pageof 22

Showing results (111-120 of 218) with videos related to

Sort By:
Pageof 22
Scientific Reports|August 4, 2025
Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositisMagdalena Röckel, Luca Musella, Corinna Preusse, et al.
Journal of the National Cancer Institute|September 14, 2014
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaKlaus G Griewank, Rajmohan Murali, Joan Anton Puig-Butille, et al.
The Journal of Dermatology|April 11, 2020
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective studyTaisuke Matsuya, Yasuhiro Nakamura, Shigeto Matsushita, et al.
International Journal of Molecular Sciences|March 25, 2022
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint InhibitionLuca Hegedüs, Elisabeth Livingstone, Ágnes Bánkfalvi, et al.
Oncotarget|September 2, 2015
Analysis of SDHD promoter mutations in various types of melanomaSimone L Scholz, Susanne Horn, Rajmohan Murali, et al.
Cancers|May 14, 2022
Genetic and Clinical Characteristics of <i>ARID1A</i> Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalCarl Maximilian Thielmann, Johanna Matull, Sebastian Roth, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsAlvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyHelen Dearden, Lewis Au, Daniel Y Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Pediatric Blood & Cancer|November 5, 2025
Melanoma of the Choroid and Ciliary Body in Children: Remission of Metastatic Melanoma of the Choroid After Treatment With Chemotherapy and Immune Checkpoint InhibitionPia Tüller, Tobias Kiefer, Leyla Jabbarli, et al.
Pageof 22